Arizona State Retirement System Buys Shares of 12,894 Replimune Group, Inc. (NASDAQ:REPL)

Arizona State Retirement System bought a new stake in shares of Replimune Group, Inc. (NASDAQ:REPLFree Report) in the 4th quarter, Holdings Channel reports. The institutional investor bought 12,894 shares of the company’s stock, valued at approximately $156,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Braidwell LP boosted its stake in Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares during the period. State Street Corp boosted its stake in Replimune Group by 102.1% in the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after purchasing an additional 1,182,181 shares during the period. Baker BROS. Advisors LP boosted its stake in Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after purchasing an additional 1,000,000 shares during the period. Parkman Healthcare Partners LLC boosted its stake in Replimune Group by 45.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock worth $8,371,000 after purchasing an additional 238,747 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after purchasing an additional 217,308 shares during the period. Institutional investors own 92.53% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Jefferies Financial Group increased their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. HC Wainwright increased their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, BMO Capital Markets increased their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $19.43.

View Our Latest Stock Analysis on Replimune Group

Replimune Group Trading Down 1.8 %

Shares of NASDAQ:REPL opened at $11.65 on Monday. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.00. The company has a market capitalization of $897.22 million, a P/E ratio of -3.79 and a beta of 1.30. The company has a 50-day simple moving average of $12.66 and a 200 day simple moving average of $12.13. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43.

Replimune Group (NASDAQ:REPLGet Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Sell-side analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

About Replimune Group

(Free Report)

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

Further Reading

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPLFree Report).

Institutional Ownership by Quarter for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.